Lv614
1970 积分 2021-10-11 加入
Selumetinib for Adults with NF1-Associated Plexiform Neurofibromas: Insights from the KOMET Study
7天前
已完结
Management of Central and Peripheral Nervous System Tumors in Patients with Neurofibromatosis
7天前
已完结
Efficacy and safety of selumetinib in patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas: a systematic review and meta-analysis
7天前
已完结
Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 study
7天前
已完结
Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 study
9天前
已完结
Efficacy and safety of selumetinib in patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas: a systematic review and meta-analysis
9天前
已完结
[Chinese guideline for the diagnosis, treatment and management of lupus nephritis (2025)]
9天前
已完结
Selumetinib in adults with NF1 and inoperable plexiform neurofibroma: a phase 2 trial
10天前
已完结
Chapter 3: Management of kidney injury caused by cancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022
10天前
已完结
Efficacy and safety of rituximab for primary nephrotic syndrome with acute kidney injury: A two-center prospective cohort study
10天前
已完结
皖公网安备34019202002308
